More on the question of optimal chemotherapy in the presence of isoniazid resistance.
Long
R
R
University of Alberta, Edmonton, Canada. richard.long@ualberta.ca
Scalcini
M
M
D000995:Antitubercular Agents / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D019353:Endemic Diseases / Q000706:statistics & numerical data; D019317:Evidence-Based Medicine; D006801:Humans; D007538:Isoniazid; D015995:Prevalence; D014376:Tuberculosis / Q000145:classification / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology*
D000995:Antitubercular Agents; D007538:Isoniazid